Department of Health

Breakthrough hepatitis C treatments

Breakthrough hepatitis C cure drugs will be available on the Pharmaceutical Benefits Scheme (PBS) from 1 March 2016 and will be accessible to all Victorians living with hepatitis C over 18 years of age. These revolutionary treatments will change the lives of all Victorians living with hepatitis C.

The new hepatitis C medicines are: sofosbuvir with ledipasvir (Harvoni); sofosbuvir (Sovaldi); daclatasvir (Daklinza); and ribavirin (Ibavyr). Treatment regimens will involve daily combinations of one to three of these drugs taken orally over a period of 8 to 24 weeks.

The new drugs eliminate the hepatitis C virus in 95-97 per cent of cases in as little as 8 weeks, and have few or no side effects. This is a major change from previously used treatments which were highly toxic and took between six and twelve months to complete with only a 50 per cent chance of clearing the virus.

The new drugs will have a dual listing on the PBS: the Section 85 listing will be for community access and the Section 100 listing is intended for prisoner access to ensure that as many people as possible are able to access the new drugs.

More detailed information on the new hepatitis C treatments is available at the Better Health Channel.

Factsheets and Frequently Asked Questions for patients and professionals regarding the new hepatitis C treatments and drugs are also available at Australian Government’s Pharmaceutical Benefits Scheme (PBS)External Link .

The Australian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) is providing education and training for the new hepatitis C treatments. The full ASHM hepatitis C treatments training program is provided in the Downloads section.

FAQ for patients

  • Hepatitis C is an infectious disease that attacks the liver, causing its inflammation, and may lead to cirrhosis, end stage liver disease, liver cancer, and in some cases death.

  • Six different genotypes of hepatitis C have been identified. Genotypes 1 and 3 are the most common causes of hepatitis C in Australia and make up 90 per cent of all cases. They are important because they help determine the treatment you need. Unlike in the past, however, your genotype is not important in terms of the chance of cure. With the treatment drugs, all six genotypes have a very high chance of cure.

  • Hepatitis C is caused by a blood borne virus and can be transmitted by infected blood through exposure to contaminated blood products, breaches in infection control in health care settings, mother to child transmission, unsafe tattooing or body piercing practices, or sharing of injecting equipment.

  • Hepatitis C is the most common blood borne virus in Australia with approximately 230,000 people currently living with hepatitis C in Australia and around 65,000 in Victoria.

    The population most at risk of acquiring hepatitis C are people who currently inject drugs including people from Aboriginal and Torres Strait Islander and culturally and linguistically diverse backgrounds, prisoners, older people, and young injectors and/or new initiates to injecting drug use.

  • Recent advances in antiviral treatment have led to the development of new highly effective drugs for the treatment of all types of hepatitis C.

    The new hepatitis C treatments are sofosbuvir with ledipasvir (Harvoni); sofosbuvir (Sovaldi); daclatasvir (Daklinza); and ribavirin (Ibavyr).

    These new treatments will be available on the Pharmaceuticals Benefits Scheme from 1 March 2016.

  • The new treatments are highly effective with a cure rate of 95-97 per cent. Treatment time is reduced to 12 weeks, drugs are tablets (rather than injections) and there are very few side effects.

    This is a major change from just a few years ago, when hepatitis C treatment time was from six to twelve months, with toxic side effects, and only a 50 percent chance of being cured.

    This means that people newly diagnosed with hepatitis C, as well as those who have been living with chronic hepatitis C for many years, will now have access to a fast, effective and well-tolerated cure.

  • The drugs are easy to take and are taken orally.

    Treatment time is usually 12 weeks. However this may range between 8 and 24 weeks for a complete course of treatment, depending on the patients genotype, whether the patient has cirrhosis, treatment history and which of the drug combinations the prescriber chooses to use.

  • The new drugs are available to all people 18 years and older. People under 18 years of age with hepatitis C should stay in touch with their GP, or contact the Royal Children’s Hospital.

  • Yes, there are no restrictions linked to former or current injecting drug use.

  • The Pharmaceutical Benefits Scheme listing means that hepatitis C patients will only pay the normal co-payment for the new drugs. The co-payment is currently worth $6.20 for patients with concessional healthcare cards and $38.30 for general patients without concessional healthcare cards, per drug, per month. For some patients needing three drugs, for example, the co-payment will therefore be $114.90 per month, or $18.60 per month concession.

    More information on co-payment charges can be found on the Commonwealth Department of Health websiteExternal Link .

  • A section 85 listing on the Pharmaceutical Benefits Scheme will allow general practitioners, as well as specialists, to prescribe the new treatments. This means that people with hepatitis C will be able to be treated by a general practitioner in the community. However, people with more advanced care needs, such as cirrhosis, may still need to see a specialist.

  • In order to prescribe, general practitioners including physicians with expertise in viral hepatitis, will be required to first consult with a gastroenterologist, hepatologist or infectious diseases physician to ensure patients with liver disease or other complex needs are appropriately referred to specialist care. A face to face consult with the specialist is not required and patients with complex needs will likely be referred to specialist care where appropriate.

    Patients affected by hepatitis C with severe or advanced liver disease may still need to access the treatments under the care of a specialist - such as a gastroenterologist, hepatologist, or an infectious disease physician with experience in treating chronic hepatitis C infection.

  • Community pharmacists will be able to dispense the drugs. However, because these are new drugs, it may take time for pharmacies to order in sufficient stock to meet demand.

    This means that patients may need to wait a couple of days after providing their script for the drugs to be available from their local pharmacy.

  • Although the drugs will be available for prescribing through the Pharmaceutical Benefits Scheme, it may be that not all GPs or pharmacists are fully aware of the new treatments by that date. This means there may be some delay in some areas in accessing the drugs from your local GP. However, the Victorian Government is working with doctors, services and hospitals to ensure these delays are minimised as much as possible.

  • Prisoners and those in custodial settings will have access to the new hepatitis C drugs through existing arrangements within the Pharmaceutical Benefits Scheme Highly Specialised Drugs Program.

Reviewed 22 September 2023


Was this page helpful?